LBRX: LB-102 demonstrates rapid efficacy and strong safety in late-stage trials for major neuropsychiatric disorders

LBRX: LB-102 demonstrates rapid efficacy and strong safety in late-stage trials for major neuropsychiatric disorders — alphai